Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Aytu BioPharma, Inc. (AYTU) had Stock-Based Compensation of $0.40M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$15.16M |
|
$-10.58M |
|
$5.54M |
|
$9.62M |
|
$17.14M |
|
$-1.97M |
|
$-8.61M |
|
$-10.58M |
|
$-10.58M |
|
$-10.58M |
|
$-10.58M |
|
$-10.58M |
|
$-10.58M |
|
$-1.97M |
|
$-1.06M |
|
10.04M |
|
10.04M |
|
$-1.05 |
|
$-1.05 |
|
| Balance Sheet Financials | |
$76.24M |
|
$0.48M |
|
$45.76M |
|
$122.00M |
|
$65.56M |
|
$10.00M |
|
$42.24M |
|
$107.80M |
|
$14.20M |
|
$-29.38M |
|
$14.20M |
|
10.73M |
|
| Cash Flow Statement Financials | |
$3.06M |
|
$-0.02M |
|
$-3.97M |
|
$30.95M |
|
$30.02M |
|
$-0.93M |
|
|
Stock-Based Compensation |
$0.40M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.16 |
|
-- |
|
-- |
|
0.41 |
|
1.47 |
|
63.46% |
|
-12.99% |
|
-12.99% |
|
-- |
|
-69.79% |
|
-69.79% |
|
$3.04M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
0.64 |
|
0.49 |
|
183.52 |
|
-74.53% |
|
36.03% |
|
-8.68% |
|
-43.74% |
|
$1.32 |
|
$0.30 |
|
$0.30 |
|